))
“Major Wins” in Lung Cancer Treatment: How “Explosion of Data” Is Changing Practice
Manage episode 407462002 series 3560609
Content provided by Jacqueline Stone and Oncololgy News Central. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jacqueline Stone and Oncololgy News Central or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Within the last few years, an “explosion of data” regarding adjuvant and neoadjuvant treatment for resectable lung cancer has contained “major wins” for patient care. Although exciting, the rapid advancement has led to questions about when chemotherapy and chemoimmunotherapy should be adopted or avoided. Bob Figlin, MD, the Steven Spielberg Family Chair in hematology-oncology at Cedars Sinai Cancer in Los Angeles, and Charu Aggarwal, MD, MPH, the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania’s Abramson Cancer Center in Philadelphia, discuss how to apply key recent findings. They also share “the special sauce” that allows Dr. Aggarwal’s team to make the best determination for surgical timing.
123 episoade
Distribuie
